drugset / Trial / NCT07391657
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethasone\], DPd \[daratumumab, pomalidomide, and dexamethasone\], PVd \[pomalidomide, bortezomib and dexamethasone\], or Kd \[carfilzomib and dexamethasone\]) in participants with RRMM.
Timeline
- Start
- 2026-02-23
- Primary completion
- 2028-06-14
- Completion
- 2030-07-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD0120 | Cell therapy | — | — |
| Comparator | Bortezomib | Small molecule | — | — |
| Comparator | Carfilzomib | Other / unclassified | — | — |
| Comparator | Daratumumab | Monoclonal antibody | — | — |
| Comparator | Dexamethasone | Small molecule | — | — |
| Comparator | Pomalidomide | Other / unclassified | — | — |